Abstract: The invention provides multichannel pipette heads and autopipettors for loading, measuring, transporting and dispensing, particularly from one micro-plate to another. An exemplary multichannel pipette head comprises a pump housing, pistons, a drive plate, an aspiration drive and bearing rails, wherein the pump housing comprises chambers adapted to receive the pistons, the pistons each comprise a shaft, the drive plate retains the pistons and translocates the piston shafts through the chambers, the aspiration drive translocates the drive plate along the bearing rails which pass through the drive plate and attach to the pump housing.

Abstract: The invention provides a human N-acetylneuraminate lyase (HNANL) and polynucleotides which identify and encode HNANL. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HNANL.

Abstract: The present invention provides a novel human tumor suppressor (NHTS) and polynucleotides which identify and encode NHTS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHTS and a method for producing NHTS. The invention also provides for agonists, antibodies, or antagonists specifically binding NHTS, and their use, in the prevention and treatment of diseases associated with expression of NHTS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHTS for the a treatment of diseases associated with the expression of NHTS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHTS.

Abstract: The present invention provides a human glutathione S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGST and a method for producing HGST. The invention also provides for agonists, antibodies, or antagonists specifically binding HGST, and their use, in the prevention and treatment of cancer and other diseases associated with the expression of HGST. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGST for the treatment of cancer and other diseases associated with the expression of HGST. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGST.

Abstract: The present invention provides a novel histamine H2 receptor (H2RH) and polynucleotides which identify and encode H2RH. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding H2RH and a method for producing H2RH. The invention also provides for agonists, antibodies, or antagonists specifically binding H2RH, and their use, in the prevention and treatment of diseases in which H2RH is expressed. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding H2RH for the treatment of diseases associated with the expression of H2RH. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding H2RH.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode TMEC, a novel human lymphotactin expressed in T-cell mixed lymphocyte reaction (TMLR). The present invention also provides for polymerase chain reaction oligomers or hybridization probes for the detection of nucleotide sequences encoding TMEC or TMEC-like molecules, antisense molecules to the nucleotide sequences which encode TMEC, diagnostic tests based on TMEC encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified TMEC, antibodies capable of binding specifically to TMEC, antagonists and inhibitors with specific binding activity for TMEC, and treatment methods.

Abstract: A method of treating wound healing with a composition containing protease nexin-I (PN-I) is disclosed. Compositions comprised of PN-I uniformly dispersed throughout a pharmaceutically acceptable carrier are disclosed as are such compositions further comprising antibiotics. Occlusive wound dressings are taught which are comprised of a support surface having an absorbent area thereon which has PN-I absorbed thereon and which absorbent area is surrounded by a pressure sensitive adhesive strip for adhering the dressing to a surface surrounding the wound to be treated.

Abstract: The gene encoding protease nexin I (PN-I) is cloned and expressed to provide practical quantities of PN-I for diagnostic and therapeutic use. PN-I is a serine protease inhibitor useful in controlling conditions mediated by proteolytic activity.